PRIMARY STUDY
Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress
Key Findings: This study showed that in intestinal epithelium cells cannabidiol (CBD) reduced intestinal inflammation, and oxidation by restoring epithelial permeability, more so than THC, CBDA, and THCA. This suggests a potential therapeutic use of CBD in the treatment and management of intestinal bowel disease (IBD).
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): Italy
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), Cannabinoid (unspecified)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype III
Receptors Studied: CB1
Route of Administration: In vitro
Citation: Cocetta V, et al. Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress. Front Pharmacol. 2021; 12:641210. doi: 10.3389/fphar.2021.641210
Authors: Cocetta V, Governa P, Borgonetti V, Tinazzi M, Peron G, Catanzaro D, Berretta M, Biagi M, Manetti F, Dall'Acqua S, Montopoli M
